238418-63-8

Upstream product

• 620630-82-2 1,2 5,6-O-di(isopropylidene)-α-D-allofuranose 
• 18530-81-9 1-((3aR,5R,6S,6aS)-6-Fluoro-2,2-dimethyl-tetrahydro-furo[2,3-d][1,3]dioxol-5-yl)-ethane-1,2-diol 
• 70722-99-5 (3aR,5R,6S,6aS)-6-fluoro-2,2-dimethyltetrahydrofuro[2,3-d][1,3]dioxole-5-carbaldehyde 
• 18530-84-2 3-deoxy-3-fluoro-1,2-O-isopropylidene-α-D-xylofuranose 

Downstream Products

• 129885-95-6 1-(3-deoxy-3-fluoro-β-D-xylofuranosyl)uracil 

Relevant academic research and scientific papers

MODIFIED RNAI AGENTS

One aspect of the present invention relates to double-stranded RNAi (dsRNA) duplex agent capable of inhibiting the expression of a target gene in vivo. The dsRNA duplex comprises one or more xylo modifications in one or both strand. Other aspects of the invention relates to pharmaceutical compositions comprising these dsRNA agents suitable for in vivo therapeutic use, and methods of inhibiting the expression of a target gene by administering these dsRNA agents, e.g., for the treatment of various disease conditions.